Tepotinib (Tepmetko)
Targeted TherapyApproved for: NSCLCBiomarker: MET Exon 14 Skipping Tepotinib (Tepmetko) is a FDA-approved treatment for adults with metastatic non-small cell lung cancer (NSCLC) who are harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. Related Research News U.S. FDA Approves Mirati’s...